- Home
- XERS
as 03-26-2025 3:38pm EST
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 526.3M | IPO Year: | 2018 |
| Target Price: | $5.92 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.69 - $6.07 | Next Earning Date: | 03-06-2025 |
| Revenue: | $203,070,000 | Revenue Growth: | 23.89% |
| Revenue Growth (this year): | 20.47% | Revenue Growth (next year): | 19.35% |
Stock Insider Trading Activity of Xeris Biopharma Holdings Inc. (XERS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hecht Beth | XERS | See Remarks | Mar 20 '25 | Sell | $5.43 | 40,000 | $217,244.00 | 1,353,510 |
Latest Xeris Biopharma Holdings Inc. News
XERS Breaking Stock News: Dive into XERS Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
Insider Monkey
8 days ago
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game
Simply Wall St.
9 days ago
Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
MT Newswires
10 days ago
Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use
Business Wire
10 days ago
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
GuruFocus.com
20 days ago
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...
Zacks
21 days ago
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
Zacks
21 days ago
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
Compare XERS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XERS Xeris Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.